{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:41:03Z","timestamp":1792654863348,"version":"4.5.0"},"reference-count":67,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA, Darmstadt, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"DOI":"10.1080\/03007995.2026.2734647","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:20:02Z","timestamp":1792653602000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of cladribine tablets for the treatment of active relapsing-remitting multiple sclerosis in the United Kingdom"],"prefix":"10.1080","author":[{"given":"Michelle","family":"Jones","sequence":"first","affiliation":[{"name":"Merck Serono (Ireland) Ltd, Dublin, Ireland, an affiliate of Merck Healthcare KGaA, Darmstadt, Germany Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatia T.","family":"Alexopoulos","sequence":"additional","affiliation":[{"name":"Merck Serono Ltd, Feltham, UK, an affiliate of Merck Healthcare KGaA, Darmstadt, Germany Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Fontrier","sequence":"additional","affiliation":[{"name":"Merck Serono Ltd, Feltham, UK, an affiliate of Merck Healthcare KGaA, Darmstadt, Germany Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-4760","authenticated-orcid":false,"given":"Gerard","family":"Harty","sequence":"additional","affiliation":[{"name":"Merck Serono Ltd, Feltham, UK, an affiliate of Merck Healthcare KGaA, Darmstadt, Germany Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Libanore","sequence":"additional","affiliation":[{"name":"Parexel International","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.08.003"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512441566"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-006-0380-z"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30481-1"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10836-8"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4905"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104581"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00847-0"},{"key":"e_1_3_5_13_1","unstructured":"European Medicines Agency (EMA). Cladribine tablets SmPC. ; 2024."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-021-00677-1"},{"key":"e_1_3_5_16_1","article-title":"MS Forward View: a consensus for the future of MS services","author":"Croft A","year":"2016","unstructured":"Croft A, Mynors G, Roberts M, et al. MS Forward View: a consensus for the future of MS services. Letchworth Garden City, Hertfordshire, UK: Multiple Sclerosis Trust. 2016.","journal-title":"Multiple Sclerosis Trust"},{"key":"e_1_3_5_17_1","volume-title":"MS Specialist Nursing in the UK 2016: report on progress towards equitable provision","author":"Mynors G","year":"2016","unstructured":"Mynors G, Bowenii A, Doncaster D. MS Specialist Nursing in the UK 2016: report on progress towards equitable provision. Letchworth Garden City, Hertfordshire, UK: Multiple Sclerosis Trust; 2016."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-abn2.175"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00654-1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00707-5"},{"key":"e_1_3_5_21_1","unstructured":"National Institute for Health and Care Excellence. Cladribine for treating relapsing-remitting multiple sclerosis (TA616). 2019."},{"key":"e_1_3_5_22_1","unstructured":"Merck Group. 2024. Great Britain is first across Europe to get regulatory approval of MAVENCLAD (cladribine tablets) as the only short course oral treatment for active Relapsing Multiple Sclerosis patients: Merck Group; https:\/\/www.merckgroup.com\/uk-en\/press-releases\/GB-Mavenclad-27-Mar-2024-Local-Press-Materials-for-Announcements-press-release-for-the-label-expansion.pdf."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"issue":"1","key":"e_1_3_5_24_1","first-page":"28","article-title":"Real-world evidence with five-year data (2017-2022) on the use of cladribine tablets in patients with multiple sclerosis in England: an updated analysis from the CLARENCE Study, in ECTRIMS","volume":"34","author":"Brownlee WA","year":"2023","unstructured":"Brownlee WA, Amerah A, Ashton L, et al. Real-world evidence with five-year data (2017-2022) on the use of cladribine tablets in patients with multiple sclerosis in England: an updated analysis from the CLARENCE Study, in ECTRIMS. Clin Neuropharmacol. 2023;34(1):28\u201335.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1461630"},{"key":"e_1_3_5_26_1","volume-title":"NICE health technology evaluations: the manual England","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual England. UK NICE; 2023."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1407303"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826070-00008"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta20810"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00018-6"},{"key":"e_1_3_5_32_1","volume-title":"Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence","author":"Tappenden P","year":"2001","unstructured":"Tappenden P, Chilcott J, O\u2019Hagan T, et al. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence. Sheffield, UK University of Sheffield School of Health and Related Research (ScHARR) Centre for Bayesian Statistics in Health Economics; 2001."},{"key":"e_1_3_5_33_1","volume-title":"The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen Southampton","author":"Peninsula Technology Assessment Group (PenTAG)","year":"2007","unstructured":"Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen Southampton. UK PenTAG; 2007. https:\/\/www.nice.org.uk\/guidance\/ta127\/resources\/multiple-sclerosis-natalizumabevaluation-report-evidence-review-group-report2."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.145805"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7370-3"},{"key":"e_1_3_5_36_1","unstructured":"National Institute for Health and Care Excellence. Cladribine for treating relapsing-remitting multiple sclerosis (TA493). 2017."},{"key":"e_1_3_5_37_1","unstructured":"National Institute for Health and Care Excellence. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527). 2018."},{"key":"e_1_3_5_38_1","unstructured":"National Institute for Health and Care Excellence. Ocrelizumab for treating relapsing\u2013remitting multiple sclerosis (TA533). 2018."},{"key":"e_1_3_5_39_1","unstructured":"National Institute for Health and Care Excellence. Peginterferon beta-1a for treating relapsing\u2013remitting multiple sclerosis (TA624). 2020."},{"key":"e_1_3_5_40_1","unstructured":"National Institute for Health and Care Excellence. Ofatumumab for treating relapsing multiple sclerosis (TA699). 2021."},{"key":"e_1_3_5_41_1","unstructured":"National Institute for Health and Care Excellence. Ponesimod for treating relapsing\u2013remitting multiple sclerosis (TA767). 2022."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107214"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.11.015"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000158"},{"key":"e_1_3_5_45_1","unstructured":"National Institute for Health and Care Excellence. British National Formulary (BNF). 2024."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.01.002"},{"key":"e_1_3_5_47_1","unstructured":"Office of National Statistics. Consumer price inflation time series (MM23). https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/dkc3\/mm23."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00144.x"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-346"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01218-7"},{"key":"e_1_3_5_51_1","unstructured":"National Institute for Health and Care Excellence. Response to stakeholder organisation comments on the draft remit and draft scope. 2024."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0718-2"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.10.002"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X19897944"},{"key":"e_1_3_5_55_1","unstructured":"National Institute for Health and Care Excellence. Final draft guidance \u2013 Cladribine for treating active relapsing forms of multiple sclerosis. 2025."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00485.x"},{"key":"e_1_3_5_57_1","unstructured":"Medicines and Healthcare products Regulatory Agency. 2024. MAVENCLAD SPC: Medicines and Healthcare products Regulatory Agency; https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/c38ba13f05ae70ae828bf9facf6ea3326a64be0b."},{"key":"e_1_3_5_58_1","volume-title":"National Schedule of Reference Costs, 2019-20","author":"Department of Health","year":"2020","unstructured":"Department of Health. National Schedule of Reference Costs, 2019-20. London, UK: NHS trusts and NHS foundation trusts; 2020."},{"key":"e_1_3_5_59_1","unstructured":"Department of Health. Drugs and pharmaceutical electronic market information (eMit). ; 2022. Pharmex data for the period 1 July 2022 to 30 June 2023 for Pharmex products shown as Generic in the period 1 January 2023 to 30 June 2023."},{"key":"e_1_3_5_60_1","unstructured":"Curtis LA Burns A. Costs of Health & Social Care 2020. 2020. Kent Academic Repository: University of Kent; pp. 185."},{"key":"e_1_3_5_61_1","volume-title":"Information on the Number and Cost of Diagnostic Test Services - PRIMARY CARE ONLY","author":"NHS Trust Pathology Department","year":"2016","unstructured":"NHS Trust Pathology Department. Information on the Number and Cost of Diagnostic Test Services - PRIMARY CARE ONLY. Barnstaple, Devon, UK: Northern Devon Healthcare; 2016."},{"key":"e_1_3_5_62_1","volume-title":"NICE guideline for Tuberculosis (NG33) Appendix H: Warwick Evidence Diagnosis of LTBI","author":"Evidence W","year":"2015","unstructured":"Evidence W, Auguste P, Tsertsvadze A, et al. NICE guideline for Tuberculosis (NG33) Appendix H: Warwick Evidence Diagnosis of LTBI. London, UK: National Institute for Health and Care Excellence; 2015."},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11110"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03668.x"},{"issue":"2","key":"e_1_3_5_65_1","first-page":"101","article-title":"Long-term survival experience of patients with multiple sclerosis","volume":"29","author":"Pokorski RJ.","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101\u2013106.","journal-title":"J Insur Med"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.08.001"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231178441"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1086362"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2734647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/03007995.2026.2734647","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2734647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:20:09Z","timestamp":1792653609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2734647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":67,"alternative-id":["10.1080\/03007995.2026.2734647"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2734647","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}